A Phase 3 interventional study of Lurasidone and Placebo in Major Depressive Disorder With Mixed Features, sponsored by Sumitomo Pharma America, Inc.. Completed at 43 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-07-15.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Depression by Sumitomo Pharma Co., Ltd. — none open to participants now, none under way, none of them phase 3. Depression · Sumitomo Pharma Co., Ltd..
Among the 11 studies in Depression by Sumitomo Pharma Co., Ltd., this one is the 6th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 3, and was the 5th registered.
8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.
Browse Depression studies →None of the 11 studies in Depression by Sumitomo Pharma Co., Ltd. is open now. The open studies under Depression, anywhere →
Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 81 across 7,078 interventional studies indexed under Depression.
Median enrollment 211 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Depression by Sumitomo Pharma Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is currently experiencing a major depressive episode (diagnosed by DSM IV TR; at least 2 weeks in duration) AND two or three of the following manic symptoms occurring on most days over at least the last 2 weeks (confirmed by the SCID-CT modified for Study D1050304):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lurasidone 20, 40 or 60 mg
Drug: Lurasidone
Placebo
Drug: Placebo
20, 40, 60 mg, flexible dose, once daily PM 6 weeks
Also known as: Latuda
Placebo
Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores
The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.
Time frame: Baseline to Week 6
Mean Change From Baseline to the 6-week Study Endpoint in the Clinical Global Impression-Severity of Illness (CGI-S) Score
The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.
Time frame: Baseline to Week 6
Mean Change From Baseline to Week 6 in the Young Mania Rating Scale (YMRS) Total Score
The YMRS is an 11-item clinician-rated instrument used to assess the severity of mania. Seven items are rated on a 5-point scale, ranging from 0 to 4, and four items are rated on a 9-point scale, ranging from 0 to 8. The YMRS total score is calculated as the sum of the 11 individual items and ranges from 0 to 60. Higher scores are associated with greater severity of mania.
Time frame: Baseline to Week 6
Mean Change From Baseline to Week 6 in the Sheehan Disability Scale (SDS) Total Score
The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors (work/school, social life/leisure, and family life/home responsibility) in the patient's life are impaired by depressive symptoms. These three items are responded to on a visual analogue scale (VAS) ranging through 0 (no impairment), 1-3 (mild), 4-6 (moderate), 7-9 (marked) and 10 (extreme) disability. The SDS total score is calculated as the sum of the three items and ranges from 0 (unimpaired) to 30 (highly impaired).
Time frame: Baseline to Week 6
Mean Change From Baseline to Week 6 in the Hamilton Rating Scale for Anxiety(HAM-A) Total Score
The HAM-A is used to quantify the severity of anxiety symptomatology and consists of 14 items. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe/disabling). The HAM-A total score is calculated as the sum of the 14 individual items and ranges from 0 to 56. Higher scores are associated with greater degree of anxiety.
Time frame: Baseline to Week 6
Percentage of Subjects Who Achieve a Response, Defined as ≥ 50% Reduction From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 (LOCF).
Time frame: Baseline to Week 6
Percentage of Subjects Who Achieve a Remission, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤ 12 at Week 6 (LOCF)
Time frame: Baseline to Week 6
| Milestone | Lurasidone | Placebo |
|---|---|---|
| Started | 109 | 102 |
| Completed | 102 | 87 |
| Not completed | 7 | 15 |
| Withdrew: Adverse event | 3 | 5 |
| Withdrew: Lack of efficacy | 2 | 4 |
| Withdrew: Protocol violation | 0 | 3 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Administrative | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores | -20.5 ± 0.95 | -13.0 ± 1.00 |
The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Mean Change From Baseline to the 6-week Study Endpoint in the Clinical Global Impression-Severity of Illness (CGI-S) Score | -1.83 ± 0.109 | -1.18 ± 0.115 |
The YMRS is an 11-item clinician-rated instrument used to assess the severity of mania. Seven items are rated on a 5-point scale, ranging from 0 to 4, and four items are rated on a 9-point scale, ranging from 0 to 8. The YMRS total score is calculated as the sum of the 11 individual items and ranges from 0 to 60. Higher scores are associated with greater severity of mania.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 6 in the Young Mania Rating Scale (YMRS) Total Score | -7.0 ± 0.35 | -4.9 ± 0.37 |
The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors (work/school, social life/leisure, and family life/home responsibility) in the patient's life are impaired by depressive symptoms. These three items are responded to on a visual analogue scale (VAS) ranging through 0 (no impairment), 1-3 (mild), 4-6 (moderate), 7-9 (marked) and 10 (extreme) disability. The SDS total score is calculated as the sum of the three items and ranges from 0 (unimpaired) to 30 (highly impaired).
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 6 in the Sheehan Disability Scale (SDS) Total Score | -11.2 ± 0.88 | -6.4 ± 0.88 |
The HAM-A is used to quantify the severity of anxiety symptomatology and consists of 14 items. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe/disabling). The HAM-A total score is calculated as the sum of the 14 individual items and ranges from 0 to 56. Higher scores are associated with greater degree of anxiety.
| units on a scale | Lurasidone | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 6 in the Hamilton Rating Scale for Anxiety(HAM-A) Total Score | -9.9 ± 0.58 | -5.4 ± 0.59 |
| percentage of subjects | Lurasidone | Placebo |
|---|---|---|
| Percentage of Subjects Who Achieve a Response, Defined as ≥ 50% Reduction From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 (LOCF). | 64.8 | 30.0 |
| percentage of subjects | Lurasidone | Placebo |
|---|---|---|
| Percentage of Subjects Who Achieve a Remission, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤ 12 at Week 6 (LOCF) | 49.1 | 23.0 |
Collected over 6 Weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone | — | 1/109 (0.9%) | 31/109 (28.4%) |
| Placebo | — | 0/100 (0%) | 29/100 (29%) |
| Event | Lurasidone | Placebo |
|---|---|---|
| Depression SuicidalPsychiatric disorders | 1/109 | 0/100 |
| Event | Lurasidone | Placebo |
|---|---|---|
| InsomniaPsychiatric disorders | 6/109 | 11/100 |
| AnxietyPsychiatric disorders | 4/109 | 9/100 |
| NauseaGastrointestinal disorders | 7/109 | 2/100 |
| HeadacheNervous system disorders | 6/109 | 6/100 |
| SomnoelenceNervous system disorders | 5/109 | 1/100 |
| Abdominal discomfortGastrointestinal disorders | 4/109 | 1/100 |
| AkathisiaNervous system disorders | 4/109 | 2/100 |
| DizzinessNervous system disorders | 4/109 | 3/100 |
| Dry mouthGastrointestinal disorders | 3/109 | 1/100 |
| Urinary Tract InfectionInfections and infestations | 1/109 | 2/100 |
Two subjects were randomized in error and were not treated.
| Age, Categorical(Participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| <=18 years | 1 | 0 | 1 |
| Between 18 and 65 years | 106 | 96 | 202 |
| >=65 years | 2 | 4 | 6 |
| Age, Continuous(years) | Lurasidone | Placebo | Total |
|---|---|---|---|
| Mean | 43.6 ± 12.08 | 46.4 ± 12.01 | 44.9 ± 12.10 |
| Sex: Female, Male(Participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| Female | 73 | 72 | 145 |
| Male | 36 | 28 | 64 |
| Race (NIH/OMB)(Participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 14 | 12 | 26 |
| White | 94 | 86 | 180 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Lurasidone | Placebo | Total |
|---|---|---|---|
| Russian Federation | 18 | 13 | 31 |
| United States | 34 | 26 | 60 |
| Ukraine | 30 | 32 | 62 |
| United Kingdom | 1 | 3 | 4 |
| Serbia | 26 | 26 | 52 |
The record gives a start of Sep 2011, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →